Abstract:Background Increasing infiltration of CD8 + T cells within tumor tissue predicts a better prognosis and is essential for response to checkpoint blocking therapy. Furthermore, current clinical protocols use unfractioned T cell populations as the starting point for transduction of chimeric antigen receptors (CARs)-modified T cells, but the optimal T cell subtype of CAR-modified T cells remains unclear. Thus, accurately identifying a group of cytotoxic T lymphocytes with high antitumor efficacy is imperative. Inspired by the theory of yin and yang, we explored a subset of CD8 + T cell in cancer with the same phenotypic characteristics as highly activated inflammatory T cells in autoimmune diseases. Methods Combination of single-cell RNA sequencing, general transcriptome sequencing data and multiparametric cytometric techniques allowed us to map CXCR6 expression on specific cell type and tissue. We applied Cxcr6 −/− mice, immune checkpoint therapies and bone marrow chimeras to identify the function of CXCR6 + CD8 + T cells. Transgenic Cxcr6 −/− OT-I mice were employed to explore the functional role of CXCR6 in antigen-specific antitumor response. Results We identified that CXCR6 was exclusively expressed on intratumoral CD8 + T cell. CXCR6 + CD8 + T cells were more immunocompetent, and chimeras with specific deficiency on CD8 + T cells showed weaker antitumor activity. In addition, Cxcr6 −/− mice could not respond to anti-PD-1 treatment effectively. High tumor expression of CXCR6 was not mainly caused by ligand-receptor chemotaxis of CXCL16/CXCR6 but induced by tumor tissue self. Induced CXCR6 + CD8 + T cells possessed tumor antigen specificity and could enhance the effect of anti-PD-1 blockade to retard tumor progression. Conclusions This study may contribute to the rational design of combined immunotherapy. Alternatively, CXCR6 may be used as a biomarker for effective CD8 + T cell state before adoptive cell therapy, providing a basis for tumor immunotherapy.

CX3CR1+CD8+ T cells: Key players in antitumor immunity

Genetically engineered T cells for cancer immunotherapy

CXCR6 is required for antitumor efficacy of intratumoral CD8 + T cell

Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy

Revisiting the CXCL13/CXCR5 Axis in the Tumor Microenvironment in the Era of Single-cell Omics: Implications for Immunotherapy

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy

Emerging Strategies in TCR-Engineered T Cells

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

CD8+ T cell-based cancer immunotherapy

CXCR6-based Immunotherapy in Autoimmune, Cancer and Inflammatory Infliction

The Role of CXCR3 and Its Ligands in Cancer

CXCL8 in Tumor Biology and Its Implications for Clinical Translation

Investigating T Cell Immunity in Cancer: Achievements and Prospects

Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy

How does TCR-T cell therapy exhibit a superior anti-tumor efficacy

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity

Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells

CXCR6 expressing T cells: Functions and role in the control of tumors

Research progress of CCR8 in tumor immunotherapy